This finding suggests that c-Jun not only promotes differentiation and suppresses tumor malignancy but also may enhance the efficacy of existing treatment modalities, such as anti-GD2 immunotherapy which is a cornerstone of high-risk neuroblastoma treatment [3, 60]. The gene discussed is JUN; the disease is neuroblastoma.